Simplification of testing and treatment in the quest to eliminate hepatitis C infection
Globally, 71 million people are living with hepatitis C virus (HCV) infection, but the burden of HCV continues to increase. Between 2015 and 2030, WHO targets include reducing new HCV infections by 80% and HCV deaths by 65%, and increasing HCV diagnoses from <20% to 90% and the number of eligible persons receiving HCV treatment from <10% to 80%. To achieve these targets, targeted interventions are needed to enhance HCV testing, linkage to care, and treatment (“the HCV care cascade”). This presentation reviews available evidence on strategies that have been successfully used to enhance HCV testing, linkage to care.
Early diagnosis of HIV and use of molecular Point-of-Care HIV testing as part of a comprehensive strategy to end HIV transmission
According to UNAIDS1 the world is embarking on a Fast-Track strategy to end the AIDS epidemic by 2030. There is a strong global consensus that powerful tools now exist to end the AIDS epidemic.
Bringing Molecular Testing Closer to the Patient
Over the past 20 years, there has been a continuous shift toward the decentralization of clinical laboratory testing. With recent advances in the speed and accuracy of point-of-care tests, it is now possible to bring molecular infectious disease testing closer to the patient. This webinar explores the benefits of molecular point-of-care testing as a means of improving patient outcomes and quality of care. Currently available testing methods are reviewed, with an emphasis on the importance of lab testing in the era of performance-driven healthcare.
Our Educational Sites
Diagnostics First
Each time a microorganism becomes resistant to an antibiotic, we lose another weapon in the war against infection. Fight back against antibiotic resistance with diagnostics first. Sign up today to receive customized, educational content and learn how on-demand molecular testing can help achieve your institution’s Infection Prevention and Antimicrobial Stewardship goals.
C. Diff FAQs
C. difficile is the leading cause of gastroenteritis-associated death1 and is associated with approximately $5 billion in excess healthcare spending2. Given the importance of accurate detection and appropriate infection control measures, diagnostics play a critical role in the management of patients with clinically significant diarrhea.
Know Your Poo
Cepheid is committed to helping infection control professionals raise awareness and drive compliance at their facilities through creative educational tools and the latest C. diff news and science. We believe when you Know Your Poo, patients win.
Journey Inside the Cepheid GeneXpert® Cartridge - 3D Animation
The cornerstone of the GeneXpert testing process is Cepheid's patented, self-contained, single use cartridge. Sample extraction, amplification and detection are all carried out within this self-contained "laboratory in a cartridge".
HPV Testing in Cape Town – See How One Clinic is Making a difference for Women
There are many health challenges, particularly for women, in South Africa. Learn how a community-based clinic research project is making a difference.
Journey Inside the Cepheid GeneXpert® Cartridge - 3D Animation
The cornerstone of the GeneXpert testing process is Cepheid's patented, self-contained, single use cartridge. Sample extraction, amplification and detection are all carried out within this self-contained "laboratory in a cartridge".
A Unique Near-Patient Strategy for Battling Hepatitis C
HPV Testing in Cape Town – See How One Clinic is Making a difference for Women
There are many health challenges, particularly for women, in South Africa. Learn how a community-based clinic research project is making a difference.
1. Hall, AJ., et al. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis. 2012. https://www.ncbi.nlm.nih.gov/pubmed/22491338
2. ModernMedicine Network. Chronic Myeloid Leukemia. Accessed Nov 27 2018. http://www.cancernetwork.com/chronic-myeloid-leukemia/chronic-myeloid-leukemia
3. Woessner, David W et al. Development of an effective therapy for chronic myelogenous leukemia. Cancer J. 2011;17(6):477-86.https://www.ncbi.nlm.nih.gov/pubmed/22157291 5.Goldberg S et al. Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia. Clin Lymph, Myel & Leuk. 2017; 18(2):98-105. https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(17)30991-6/fulltext